Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome

Purpose of Review: This article reviews the clinical presentations, diagnostic findings, and treatment options for autoimmune myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome. Recent Findings: Immunologic research is unraveling the immunopathology of MG and identifying targets for novel immune-based therapy of this condition. MG patients with antibodies to muscle-specific tyrosine kinase (MuSK) frequently present with symptoms and clinical findings that suggest nerve or muscle disease. Summary: Early diagnosis and treatment have a marked effect on outcome in these diseases. In most cases, the diagnosis of MG or Lambert-Eaton myasthenic syndrome can be made from the history, supplemented with directed questions, and a physical examination designed to demonstrate variable weakness in affected muscle groups. Appropriate confirmatory tests almost always establish the diagnosis. Although several novel treatment modalities for MG are under investigation, currently available therapies produce substantial improvement in function and quality of life in most patients with this condition. Knowledge about the dosing, adverse effects, and costs of immunomodulatory therapies is essential for the effective management of patients with MG and Lambert-Eaton myasthenic syndrome.

[1]  S. Berrih-Aknin,et al.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. , 2014, Journal of autoimmunity.

[2]  G. Cutter,et al.  Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? , 2014, Muscle & nerve.

[3]  R. Lewis,et al.  Autoantibodies to Agrin in Myasthenia Gravis Patients , 2014, PloS one.

[4]  D. Sanders,et al.  Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? , 2014, Muscle & nerve.

[5]  L. Padua,et al.  Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. , 2013, Autoimmunity reviews.

[6]  D. Sanders.  Measuring jitter with concentric needle electrodes , 2013, Muscle & nerve.

[7]  J. Howard.  The Diagnosis of Myasthenia Gravis and Other Disorders of Neuromuscular Transmission , 2012 .

[8]  J. Verschuuren,et al.  Long-lasting treatment effect of rituximab in MuSK myasthenia , 2012, Neurology.

[9]  D. Sanders.  Approach to Diseases of the Neuromuscular Junction , 2011 .

[10]  D. Sanders,et al.  Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts , 2011, Muscle & nerve.

[11]  Y. Yamanashi,et al.  Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis , 2011, Annals of neurology.

[12]  J. Verschuuren,et al.  3,4-diaminopyridine for the treatment of Lambert–Eaton myasthenic syndrome , 2010, Expert review of clinical immunology.

[13]  D. Sanders,et al.  Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. , 2010, Current opinion in neurology.

[14]  D. Sanders,et al.  Immunosuppressive therapies in myasthenia gravis , 2010, Autoimmunity.

[15]  M. Conaway,et al.  Mycophenolate mofetil in AChR‐antibody‐positive myasthenia gravis: Outcomes in 102 patients , 2010, Muscle & nerve.

[16]  M. Farrugia,et al.  The use of rituximab in myasthenia gravis and Lambert–Eaton myasthenic syndrome , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  E. Stålberg,et al.  Acetylcholinesterase inhibitors in MG: To be or not to be? , 2009, Muscle & nerve.

[18]  R. Conwit,et al.  The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial , 2008, Journal of Neuroimmunology.

[19]  D. Richman,et al.  An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis , 2008, Neurology.

[20]  A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis , 2008, Neurology.

[21]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[22]  D. Sanders,et al.  MuSK-antibody positive myasthenia gravis: Clinical and electrodiagnostic patterns , 2005, Clinical Neurophysiology.

[23]  V. Lennon,et al.  Autoantibody Profiles and Neurological Correlations of Thymoma , 2004, Clinical Cancer Research.

[24]  R. Pascuzzi.  The Edrophonium Test , 2003, Seminars in neurology.

[25]  A. Vincent,et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.

[26]  G. Gronseth,et al.  Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) , 2000, Neurology.

[27]  D. Sanders,et al.  Lambert-Eaton myasthenic syndrome: Electrodiagnostic findings and response to treatment , 2000, Neurology.

[28]  Edsel Ing,et al.  The complication rate of edrophonium testing for suspected myasthenia gravis. , 2000, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[29]  D. Sanders,et al.  Associations between circulating sex steroid hormones and cognition in normal elderly women , 2000, Neurology.

[30]  C. Chalk,et al.  Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinoma , 1990, Neurology.

[31]  J. Simpson.  Pathogenesis of myasthenia gravis. , 1971, British medical journal.

[32]  A. Tessitore,et al.  Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. , 2010, The Annals of thoracic surgery.

[33]  D. Sanders,et al.  Clinical features of myasthenia gravis. , 2008, Handbook of clinical neurology.

[34]  J. Newsom-Davis,et al.  Treatment for Lambert-Eaton myasthenic syndrome. , 2005, The Cochrane database of systematic reviews.